Suven Life Sciences rose 3.5% to Rs 76.90 at 10:57 IST on BSE after the firm said it has received 3 product patents one each from Canada, China and India corresponding to NCEs for treatment of disorders associated with neurodegenerative diseases.
The announcement was made during trading hours today, 31 January 2014.
Meanwhile, the S&P BSE Sensex was down 2.76 points or 0.01% at 20,495.49.
On BSE, so far 2.45 lakh shares were traded in the counter as against average daily volume of 4.51 lakh shares in the past one quarter.
The stock hit a high of Rs 78.30 and a low of Rs 75 so far during the day. The stock had hit a record high of Rs 83.40 on 12 November 2013. The stock had hit a 52-week low of Rs 22 on 4 March 2013.
The stock had outperformed the market over the past one month till 30 January 2014, rising 0.07% compared with the Sensex's 3.05% fall. The scrip had also outperformed the market in past one quarter, surging 37.47 % as against Sensex's 2.55% fall.
More From This Section
The small-cap company has equity capital of Rs 11.68 crore. Face value per share is Re 1.
Suven Life Sciences (Suven) announced today, 31 January 2014 the grant of three product patents one each from Canada and India corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2025.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia, Suven said in a statement.
With these new patents, Suven has a total of fourteen granted patents from Canada, twelve granted patents from China and seventeen granted patents from India. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts, the company said. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, Suven said in a statement.
Venkat Jasti, CEO, Suven Life Sciences said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally".
Suven Life Sciences' net profit galloped 601.8% to Rs 45.55 crore on 201.3% growth in net sales to Rs 151.41 crore in Q2 September 2013 over Q2 September 2012.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products. The company has twelve internallydiscovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
Powered by Capital Market - Live News